Clinical Trial

Filter Lifespan in Continuous Renal Replacement Therapy

Study acronym: CRRTInfO
Recruiting
View on ClinicalTrials.gov →
Record status
This record was last updated December 12, 2024 (before its estimated May 2025 completion). Its status may not reflect the trial's current state.
Summary
The only supportive therapy for patients with AKI is renal replacement therapy (RRT). In the ICU setting, continuous RRT (CRRT) is mostly favored. In a post-hoc analysis of the RICH trial (regional citrate versus systemic heparin anticoagulation for CRRT in critically ill patient with AKI), it was shown that the filter life span is associated with an increased rate of new infection and that the type of anticoagulants did not directly affect infection rate. The mechanisms of this infection rate is unknown.
Protocol Amendment History 5 amendments
This ClinicalTrials.gov record has been amended 5 times since 2022-07-05; most recent amendment 2024-12-06.
Status change: Not Yet Recruiting → Recruiting 2023-03-23
Trial Details
NCT Number NCT05450185
Lead Sponsor University Hospital Muenster
Collaborators: Baxter Healthcare Corporation
Conditions Critically Ill, Continuous Renal Replacement Therapy, Infections
Enrollment 600 participants
Start Date 2023-03-02
Primary Completion 2025-05 (estimated)
Study Completion 2025-08 (estimated)
Updated on ClinicalTrials.gov 2024-12-12